Selected research
Market Structure
Global Viral Gene Therapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Viral Gene Therapy market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The US & Canada market for Viral Gene Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Viral Gene Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Viral Gene Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Viral Gene Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Viral Gene Therapy include AnGes, Catalent, Ionis Pharmaceuticals, Orchard Therapeutics, Sarepta Therapeutics, SIBIONO, Spark Therapeutics, Amgen and Biogen, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Includes
This report provides an overview of the global Viral Gene Therapy market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Viral Gene Therapy and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Viral Gene Therapy revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Viral Gene Therapy market size, projected growth trends, production technologies, key applications, and end-use industries.
Viral Gene Therapy Segment by Company
AnGes
Catalent
Ionis Pharmaceuticals
Orchard Therapeutics
Sarepta Therapeutics
SIBIONO
Spark Therapeutics
Amgen
Biogen
Gilead Sciences
Lonza
Novartis
Shanghai Sunway Biotech
Viral Gene Therapy Segment by Type
Integrating Viral Vectors
Non-Integrating Viral Vectors
Viral Gene Therapy Segment by Application
Ophthalmologic Diseases
Hematologic Diseases
Cardiovascular Diseases
Muscular Diseases
Metabolic Diseases
Infectious Diseases
Others
Viral Gene Therapy Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Viral Gene Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Viral Gene Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Viral Gene Therapy.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Viral Gene Therapy in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Viral Gene Therapy industry.
Chapter 3: Detailed analysis of Viral Gene Therapy companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Viral Gene Therapyrevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Integrating Viral Vectors
- Non-Integrating Viral Vectors
Applications
- Ophthalmologic Diseases
- Hematologic Diseases
- Cardiovascular Diseases
- Muscular Diseases
- Metabolic Diseases
- Infectious Diseases
- Others
Companies covered
- AnGes
- Catalent
- Ionis Pharmaceuticals
- Orchard Therapeutics
- Sarepta Therapeutics
- SIBIONO
- Spark Therapeutics
- Amgen
- Biogen
- Gilead Sciences
- Lonza
- Novartis
- Shanghai Sunway Biotech
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global Viral Gene Therapy Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 Integrating Viral Vectors
- 1.2.3 Non-Integrating Viral Vectors
- 1.3 Market Analysis by Application
- 1.3.1 Global Viral Gene Therapy Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Ophthalmologic Diseases
- 1.3.3 Hematologic Diseases
- 1.3.4 Cardiovascular Diseases
- 1.3.5 Muscular Diseases
- 1.3.6 Metabolic Diseases
- 1.3.7 Infectious Diseases
- 1.3.8 Others
- 1.4 Global Market Growth Prospects
- 1.5 Global Viral Gene Therapy Growth Trends by Region
- 1.5.1 Global Viral Gene Therapy Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 Viral Gene Therapy Market Size by Region (2021-2026)
- 1.5.3 Viral Gene Therapy Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global Viral Gene Therapy Market Dynamics
- 2.1 Viral Gene Therapy Industry Trends
- 2.2 Viral Gene Therapy Industry Drivers
- 2.3 Viral Gene Therapy Industry Opportunities and Challenges
- 2.4 Viral Gene Therapy Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global Viral Gene Therapy Revenue by Company (2021-2026)
- 3.2 Global Viral Gene Therapy Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global Viral Gene Therapy Key Company Head office and Area Served
- 3.4 Global Viral Gene Therapy Company, Product Type & Application
- 3.5 Global Viral Gene Therapy Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global Viral Gene Therapy Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 Viral Gene Therapy Players Market Share by Revenue in 2025
- 3.6.3 2025 Viral Gene Therapy Tier 1, Tier 2, and Tier 3
4 Viral Gene Therapy Market by Type
- 4.1 Global Viral Gene Therapy Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global Viral Gene Therapy Market Size by Type (2021-2032)
- 4.3 Global Viral Gene Therapy Market Size Share by Type (2021-2032)
5 Viral Gene Therapy Market by Application
- 5.1 Global Viral Gene Therapy Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global Viral Gene Therapy Market Size by Application (2021-2032)
- 5.3 Global Viral Gene Therapy Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 AnGes
- 6.1.1 AnGes Company Information
- 6.1.2 AnGes Business Overview
- 6.1.3 AnGes Viral Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 AnGes Viral Gene Therapy Product Portfolio
- 6.1.5 AnGes Recent Developments
- 6.2 Catalent
- 6.2.1 Catalent Company Information
- 6.2.2 Catalent Business Overview
- 6.2.3 Catalent Viral Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 Catalent Viral Gene Therapy Product Portfolio
- 6.2.5 Catalent Recent Developments
- 6.3 Ionis Pharmaceuticals
- 6.3.1 Ionis Pharmaceuticals Company Information
- 6.3.2 Ionis Pharmaceuticals Business Overview
- 6.3.3 Ionis Pharmaceuticals Viral Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 Ionis Pharmaceuticals Viral Gene Therapy Product Portfolio
- 6.3.5 Ionis Pharmaceuticals Recent Developments
- 6.4 Orchard Therapeutics
- 6.4.1 Orchard Therapeutics Company Information
- 6.4.2 Orchard Therapeutics Business Overview
- 6.4.3 Orchard Therapeutics Viral Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 Orchard Therapeutics Viral Gene Therapy Product Portfolio
- 6.4.5 Orchard Therapeutics Recent Developments
- 6.5 Sarepta Therapeutics
- 6.5.1 Sarepta Therapeutics Company Information
- 6.5.2 Sarepta Therapeutics Business Overview
- 6.5.3 Sarepta Therapeutics Viral Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 Sarepta Therapeutics Viral Gene Therapy Product Portfolio
- 6.5.5 Sarepta Therapeutics Recent Developments
- 6.6 SIBIONO
- 6.6.1 SIBIONO Company Information
- 6.6.2 SIBIONO Business Overview
- 6.6.3 SIBIONO Viral Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 SIBIONO Viral Gene Therapy Product Portfolio
- 6.6.5 SIBIONO Recent Developments
- 6.7 Spark Therapeutics
- 6.7.1 Spark Therapeutics Company Information
- 6.7.2 Spark Therapeutics Business Overview
- 6.7.3 Spark Therapeutics Viral Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.7.4 Spark Therapeutics Viral Gene Therapy Product Portfolio
- 6.7.5 Spark Therapeutics Recent Developments
- 6.8 Amgen
- 6.8.1 Amgen Company Information
- 6.8.2 Amgen Business Overview
- 6.8.3 Amgen Viral Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.8.4 Amgen Viral Gene Therapy Product Portfolio
- 6.8.5 Amgen Recent Developments
- 6.9 Biogen
- 6.9.1 Biogen Company Information
- 6.9.2 Biogen Business Overview
- 6.9.3 Biogen Viral Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.9.4 Biogen Viral Gene Therapy Product Portfolio
- 6.9.5 Biogen Recent Developments
- 6.10 Gilead Sciences
- 6.10.1 Gilead Sciences Company Information
- 6.10.2 Gilead Sciences Business Overview
- 6.10.3 Gilead Sciences Viral Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.10.4 Gilead Sciences Viral Gene Therapy Product Portfolio
- 6.10.5 Gilead Sciences Recent Developments
- 6.11 Lonza
- 6.11.1 Lonza Company Information
- 6.11.2 Lonza Business Overview
- 6.11.3 Lonza Viral Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.11.4 Lonza Viral Gene Therapy Product Portfolio
- 6.11.5 Lonza Recent Developments
- 6.12 Novartis
- 6.12.1 Novartis Company Information
- 6.12.2 Novartis Business Overview
- 6.12.3 Novartis Viral Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.12.4 Novartis Viral Gene Therapy Product Portfolio
- 6.12.5 Novartis Recent Developments
- 6.13 Shanghai Sunway Biotech
- 6.13.1 Shanghai Sunway Biotech Company Information
- 6.13.2 Shanghai Sunway Biotech Business Overview
- 6.13.3 Shanghai Sunway Biotech Viral Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.13.4 Shanghai Sunway Biotech Viral Gene Therapy Product Portfolio
- 6.13.5 Shanghai Sunway Biotech Recent Developments
7 North America
- 7.1 North America Viral Gene Therapy Market Size (2021-2032)
- 7.2 North America Viral Gene Therapy Market Size by Type
- 7.2.1 North America Viral Gene Therapy Market Size by Type (2021-2026)
- 7.2.2 North America Viral Gene Therapy Market Size by Type (2027-2032)
- 7.2.3 North America Viral Gene Therapy Market Share by Type (2021-2032)
- 7.3 North America Viral Gene Therapy Market Size by Application
- 7.3.1 North America Viral Gene Therapy Market Size by Application (2021-2026)
- 7.3.2 North America Viral Gene Therapy Market Size by Application (2027-2032)
- 7.3.3 North America Viral Gene Therapy Market Share by Application (2021-2032)
- 7.4 North America Viral Gene Therapy Market Size by Country
- 7.4.1 North America Viral Gene Therapy Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America Viral Gene Therapy Market Size by Country (2021-2026)
- 7.4.3 North America Viral Gene Therapy Market Size by Country (2027-2032)
- 7.4.4 North America Viral Gene Therapy Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe Viral Gene Therapy Market Size (2021-2032)
- 8.2 Europe Viral Gene Therapy Market Size by Type
- 8.2.1 Europe Viral Gene Therapy Market Size by Type (2021-2026)
- 8.2.2 Europe Viral Gene Therapy Market Size by Type (2027-2032)
- 8.2.3 Europe Viral Gene Therapy Market Share by Type (2021-2032)
- 8.3 Europe Viral Gene Therapy Market Size by Application
- 8.3.1 Europe Viral Gene Therapy Market Size by Application (2021-2026)
- 8.3.2 Europe Viral Gene Therapy Market Size by Application (2027-2032)
- 8.3.3 Europe Viral Gene Therapy Market Share by Application (2021-2032)
- 8.4 Europe Viral Gene Therapy Market Size by Country
- 8.4.1 Europe Viral Gene Therapy Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe Viral Gene Therapy Market Size by Country (2021-2026)
- 8.4.3 Europe Viral Gene Therapy Market Size by Country (2027-2032)
- 8.4.4 Europe Viral Gene Therapy Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China Viral Gene Therapy Market Size (2021-2032)
- 9.2 China Viral Gene Therapy Market Size by Type
- 9.2.1 China Viral Gene Therapy Market Size by Type (2021-2026)
- 9.2.2 China Viral Gene Therapy Market Size by Type (2027-2032)
- 9.2.3 China Viral Gene Therapy Market Share by Type (2021-2032)
- 9.3 China Viral Gene Therapy Market Size by Application
- 9.3.1 China Viral Gene Therapy Market Size by Application (2021-2026)
- 9.3.2 China Viral Gene Therapy Market Size by Application (2027-2032)
- 9.3.3 China Viral Gene Therapy Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia Viral Gene Therapy Market Size (2021-2032)
- 10.2 Asia Viral Gene Therapy Market Size by Type
- 10.2.1 Asia Viral Gene Therapy Market Size by Type (2021-2026)
- 10.2.2 Asia Viral Gene Therapy Market Size by Type (2027-2032)
- 10.2.3 Asia Viral Gene Therapy Market Share by Type (2021-2032)
- 10.3 Asia Viral Gene Therapy Market Size by Application
- 10.3.1 Asia Viral Gene Therapy Market Size by Application (2021-2026)
- 10.3.2 Asia Viral Gene Therapy Market Size by Application (2027-2032)
- 10.3.3 Asia Viral Gene Therapy Market Share by Application (2021-2032)
- 10.4 Asia Viral Gene Therapy Market Size by Country
- 10.4.1 Asia Viral Gene Therapy Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia Viral Gene Therapy Market Size by Country (2021-2026)
- 10.4.3 Asia Viral Gene Therapy Market Size by Country (2027-2032)
- 10.4.4 Asia Viral Gene Therapy Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa Viral Gene Therapy Market Size (2021-2032)
- 11.2 South America, Middle East & Africa Viral Gene Therapy Market Size by Type
- 11.2.1 South America, Middle East & Africa Viral Gene Therapy Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa Viral Gene Therapy Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa Viral Gene Therapy Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa Viral Gene Therapy Market Size by Application
- 11.3.1 South America, Middle East & Africa Viral Gene Therapy Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa Viral Gene Therapy Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa Viral Gene Therapy Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa Viral Gene Therapy Market Size by Country
- 11.4.1 South America, Middle East & Africa Viral Gene Therapy Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa Viral Gene Therapy Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa Viral Gene Therapy Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa Viral Gene Therapy Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst